Trial Profile
Phase I trial of interleukin-12 in combination with paclitaxel plus Herceptin [trastuzumab] in patients with HER2-positive malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Interleukin-12 (Primary) ; Paclitaxel; Trastuzumab
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2010 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 30 Sep 2005 New trial record.